ASKA Pharmaceutical Holdings CO., Ltd.JP:4886
| Mar 31,
2022 | Mar 31,
2023 | Mar 31,
2024 |
|---|
| Profit (loss) before income taxes | 6,163 | 5,357 | 9,862 |
|---|
| Depreciation | 2,885 | 3,127 | 2,662 |
|---|
| Increase (decrease) in retirement benefit asset and liability | - | -153 | -5,262 |
|---|
| Interest and dividend income | -258 | -338 | -335 |
|---|
| Interest expenses | 56 | 50 | 40 |
|---|
| Share of loss (profit) of entities accounted for using equity method | -18 | 19 | 41 |
|---|
| Loss (gain) on sale and retirement of property, plant and equipment | -9,419 | 6 | 2 |
|---|
| Loss (gain) on sale of investment securities | - | -124 | -3,340 |
|---|
| Decrease (increase) in trade receivables | -1,361 | -742 | -370 |
|---|
| Decrease (increase) in inventories | -687 | -2,627 | -2,713 |
|---|
| Increase (decrease) in trade payables | 412 | -980 | 1,494 |
|---|
| Other, net | 503 | 322 | 642 |
|---|
| Subtotal | 4,863 | 3,916 | 2,724 |
|---|
| Interest and dividends received | 292 | 337 | 414 |
|---|
| Interest paid | -58 | -51 | -41 |
|---|
| Income taxes paid | -1,385 | -850 | -1,611 |
|---|
| Net cash provided by (used in) operating activities | 2,842 | 3,351 | 1,486 |
|---|
| Proceeds from redemption of securities | - | - | 400 |
|---|
| Purchase of securities | - | -400 | -500 |
|---|
| Purchase of property, plant and equipment | -579 | -461 | -1,320 |
|---|
| Proceeds from sale of property, plant and equipment | 10,312 | - | 1 |
|---|
| Purchase of intangible assets | -1,798 | -285 | -133 |
|---|
| Purchase of investment securities | -56 | - | -352 |
|---|
| Proceeds from sale of investment securities | 11 | 190 | 4,230 |
|---|
| Purchase of shares of subsidiaries and associates | -53 | - | -1,464 |
|---|
| Other, net | -1,091 | -170 | 845 |
|---|
| Net cash provided by (used in) investing activities | 6,743 | -1,126 | 1,706 |
|---|
| Repayments of long-term borrowings | -2,298 | -1,423 | -3,138 |
|---|
| Net decrease (increase) in treasury shares | -248 | 55 | 9 |
|---|
| Dividends paid | -398 | -452 | -792 |
|---|
| Other, net | - | - | -22 |
|---|
| Net cash provided by (used in) financing activities | -2,996 | -1,820 | -3,943 |
|---|
| Effect of exchange rate change on cash and cash equivalents | - | -2 | -15 |
|---|
| Net increase (decrease) in cash and cash equivalents | 6,589 | 402 | -766 |
|---|